Breast Cancer Academy

[Corriere della Sera @Corriere]

Elena Cecchettin, sorella di Giulia uccisa dall'ex fidanzato Filippo Turetta l'11 novembre 2023, ha continuato a fare rumore per Giulia e a gridare contro una cultura dove «nessun uomo è buono se non fa nulla per smantellare la società che li privilegia tanto». Il 12 maggio Elena sarà al Salone Internazionale del Libro di Torino con Alessandra Campani, socia fondatrice dell’associazione Nondasola, e Barbara Stefanelli, vicedirettrice vicaria del Corriere della Sera per incontrare le ragazze e i ragazzi. Qui potete inviarci le vostre domande per lei: ne discuteremo al Salone
https://t.co/aSAbTXcAH4

[Benedetta Conte @BenedettaConte5]

Very happy to see that our paper on @eBioMedicine is the Editor's pick from the April issue! B-cell immunity is finally gaining its spot in the onocoimmunology field. In this paper we show how it is associated with pCR and prognosis in TNBC ⬇️@prat_aleix @evomet_itn @fara_bm

[Breast Cancer Academy @BCancerAcademy]

On-line nuovi materiali!

📚Disponibili i materiali (PDF, video) del webinar di dicembre che ha presentato una selezione di lavori presentati all'ultimo San Antonio Breast Cancer Symposium.

https://t.co/wRww60BzDq

#breastcancer #SABCS23 #oncology

[Fabio Puglisi @puglisi_fabio]

🔬Breaking barriers in #TNBC Unleashing the power of #ADCs 👉🏼 https://t.co/Iq5OM0hpuY Thanks to Arianna Dri and the extraordinary group of coauthors @arpino_grazia 
@BianchiniGP @curijoey 
@MicheleDelauren @delmastro_lucia @alessandrafab11 @ALEDIGNUS12 
@valeguarneri

[Ospedale San Martino Genova @SanMartino_Ge]

L’analisi di un gene potrà rivelare il periodo ideale di trattamento per minimizzare i rischi e amplificare i benefici in ogni donna colpita da tumore al seno positivo per i recettori ormonali.
Studio finanziato da @MinisteroSalute

Leggi di più 👇
https://t.co/LOd2jtl1P1

@AACR

[Breast Cancer Academy @BCancerAcademy]

WEBINAR LIVE
Breast Cancer Academy: le novità da San Antonio
1,5 Crediti ECM | 18 dicembre 2023

ISCRIVITI ORA
https://t.co/s64hTQXp1x

#breastcancer #SABCS23 #oncology

[Diletta Favero @DilettaFav]

Honoured of presenting the first safety analysis of the GIM26 - TRASTHER study at the oral communication session of #AIOM23 congress.

Key topics: real world evidence, post-neoadjuvant T-DM1, safety data

@UniGenova @GIM @AIOMtweet

[Federica Miglietta @FedeMiglietta]

We are so glad to share our immuno-genomic model for HR+/HER2- eBC based on the integrated evaluation of Recurrence Score & TILs.
💡Just out on European Journal of Cancer
@vitti10
https://t.co/Ypua5M4XrE

[Breast Cancer Academy @BCancerAcademy]

SNPs of aromatase could be useful e biomarkers to personalize both extended andjuvant endocrine treatment and survivorship intervention in patients with ER+ early #breastcancer . Validation needed!
⬇️⬇️⬇️⬇️⬇️

[Benedetta Conte @BenedettaConte5]

🚨🚨 Promising biomarker to select patients for extended adjuvant aromatase inhibitors in patients with #breastcancer 🚨🚨

Article out today in @CCR_AACR
open access
https://t.co/lnILwIi3IM

⬇ Thread follows @matteolambe @prat_aleix @OncoAlert @UniGenova @FrancescoSche20

[Elia Seguí, MD @elia_segui]

Happy to share at #ESMO23 our work (2239P) on gene signatures capturing tertiary lymphoid structures (TLS) from pts prescreened at @SOLTI ACROPOLI trial ➡️ 14-gene B-cell signature IGG strongly associated with TLS across cancer types! @prat_aleix @TomasPascualMD @hospitalclinic

[Accademia Medicina @ACCMEDorg]

Si è concluso il 19th Meet The Professor | Advanced International Breast Cancer Course (AIBCC).
Un ringraziamento speciale va ai Resp. Scientifici Pierfranco Conte, Valentina Guarneri, Philip Poortmans e @prat_aleix Prat e ai membri del Comitato Scientifico Internazionale.

[eClinicalMedicine – The Lancet Discovery Science @eClinicalMed]

Impact of the endocrine resistance/sensitivity classification according to consensus guidelines for advanced #BreastCancer

Findings provide evidence on prognostic and clinical impact of the currently adopted classification in HR+/HER2− advanced BC

https://t.co/RCUl7LIlMg

[Benedetta Conte @BenedettaConte5]

Outstanding @fara_bm at #ESMOBreast23 on HER2/ERBB2 mRNA leves and response to HER3-DXd in @_SOLTI TOTHER3 trial

Lower ERBB2 👉better response from HER3-DXd
Biological explanation still unknown. Maybe the answer is the HER2-HER3 dimerization affecting HER3 stability?

[Benedetta Conte @BenedettaConte5]

Jee Hyun Kim at #ESMOBreast23 on biomarker-driven strategies in HER2+ BC. Genomic biomarkers predict prognosis beyond clinical factors. Assays integrating both like #HER2DX can better guide tx. More evidence available at the poster display tomorrow at 12.15 @RevealGenomics

[Benedetta Conte @BenedettaConte5]

Great talk by @prat_aleix on HR+/HER2 BC biomarkers. My fav part:
basal-like and immunogenic phenotypes can be found in HR+/HER2- too (even in ER>10%!), and are associated with 👎response to endocrine tp and 👍 response to chemo (and maybe IO) #ESMOBreast23

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

In case you missed it! 👉Landmark #POSITIVE study published in @NEJM by Dr. Ann Partridge and colleagues which helps us understand the impact of Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
#breastcancer #bcsm #pregnancy
https://t.co/mTyiNJEFx8

[ONcotwITting @ONcotwITting]

HER2: bersaglio mobile? https://t.co/RMxnlj8QPc

[Paolo Tarantino @PTarantinoMD]

One of the most thought provoking and brilliant works in the HER2-low space.

👉most patients with HER2-neg MBC simultaneously harbor both HER2-0 and HER2-low lesions, even within the same organ.

Congrats Tatjana Geukens & colleagues for the publication!
https://t.co/7KMxbqZVg0

[Breast Cancer Academy @BCancerAcademy]

I DUBBI DI MARTA | Podcast
Le risposte della BCA alle domande delle pazienti
🔗https://t.co/PV3ZxzTQFh

🔊 24 - Cos'è l'immunoterapia e quando si usa nel tumore della mammella? Risponde @AlessiaRognone

#breastcancer #Immunotherapy

https://t.co/dzIBKU2XYd

[Breast Cancer Academy @BCancerAcademy]

On-line nuovi materiali!

📚Confronto del valore prognostico e predittivo dell’espressione genica immuno relata vs infiltrato linfocitario tumorale nel ca. mammario HER2+ in stadio precoce - A cura di Z. Ballatore (AN)
https://t.co/TNynaEdmKr

https://t.co/U7T9T5UzqE
@JAMAOnc